PSMA引导的转移灶定向治疗用于寡转移性肾细胞癌:概念验证性PEDESTAL研究
该概念验证研究基于PSMA PET/CT数据库,纳入2014至2020年接受转移灶定向治疗的寡转移性肾细胞癌患者,共34例、60个病灶,中位随访4.1年。PSMA引导的转移灶定向治疗显示出持久的肿瘤学结局,5年局部无进展生存率85%。
要点
- 34例寡转移性肾细胞癌患者接受PSMA引导的转移灶定向治疗,共治疗60个病灶。
- 5年局部无进展生存率85%,5年总生存率64%,5年无进展生存率8%。
- 5年免于系统治疗策略改变率43%。
核心结论
- 在这项概念验证研究中,PSMA引导的转移灶定向治疗为寡转移性肾细胞癌提供了持久的肿瘤学结局,即使随访至5年。
- 据作者所知,这是首个统一接受PSMA引导的转移灶定向治疗的队列,也是寡转移性肾细胞癌转移灶定向治疗随访时间最长的研究之一。
- 随着可及性提高,PSMA PET/CT可快速用于筛选适合转移灶定向治疗的患者并改善寡转移性肾细胞癌患者的结局。
研究设计与样本
- 概念验证研究,查询PSMA PET/CT数据库,纳入2014至2020年接受转移灶定向治疗的寡转移性肾细胞癌患者。
- 共检索3095份PSMA PET/CT扫描,识别83例肾细胞癌患者,其中34例接受转移灶定向治疗,涉及60个病灶。
- 中位随访4.1年;6例(18%)为同时性转移性疾病;转移灶数目中位数1个(四分位距1-2个)。
主要发现
- 常见转移部位为骨(19个,32%)和肺(19个,32%)。
- 放疗照射56个转移灶(93%),其中立体定向消融放疗38个、常规放疗18个;4个(7%)接受手术。
- 1年、3年、5年局部无进展生存率分别为94%(95%CI 85%-98%)、85%(95%CI 69%-94%)、85%(95%CI 69%-94%)。
- 1年、3年、5年总生存率分别为88%(95%CI 71%-95%)、71%(95%CI 52%-84%)、64%(95%CI 45%-79%)。
- 1年、3年、5年无进展生存率分别为47%(95%CI 30%-63%)、26%(95%CI 13%-42%)、8%(95%CI 2%-22%);1年、3年、5年免于系统治疗策略改变率分别为76%(95%CI 57%-87%)、65%(95%CI 45%-79%)、43%(95%CI 19%-65%)。
临床怎么用
- 作者认为,随着可及性提高,PSMA PET/CT可快速用于筛选适合转移灶定向治疗的寡转移性肾细胞癌患者并改善其结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metastasis-directed therapy (MDT) in oligometastatic renal cell carcinoma (RCC) is typically based on conventional imaging. Prostate-specific membrane antigen (PSMA) PET/CT has shown superiority over conventional imaging. Our objective was to perform a proof-of-concept study to evaluate the efficacy of PSMA-guided MDT in oligometastatic RCC. Methods: A PSMA PET/CT database was queried for oligometastatic RCC patients undergoing MDT from 2014 to 2020. The primary endpoint was progression-free survival. Secondary endpoints included freedom from local progression, freedom from change in systemic therapy strategy, and overall survival. Results: A search of 3,095 PSMA PET/CT scans identified 83 RCC patients and 34 receiving MDT to 60 sites. The median follow-up was 4.1 y. Six patients (18%) had synchronous metastatic disease. The median number of metastases was 1 (interquartile range, 1-2). Common sites included bone (19, 32%) and lung (19, 32%). Radiation therapy was delivered to 56 metastases (93%), including stereotactic ablative body and conventional radiotherapy (38 and 18 metastases, respectively), and 4 (7%) underwent surgery. One-, 3-, and 5-y freedom from local progression was 94% (95% CI, 85%-98%), 85% (95% CI, 69%-94%), and 85% (95% CI, 69%-94%), respectively. One-, 3-, and 5-y overall survival was 88% (95% CI, 71%-95%), 71% (95% CI, 52%-84%), and 64% (95% CI, 45%-79%), respectively. One-, 3-, and 5-y progression-free survival was 47% (95% CI, 30%-63%), 26% (95% CI, 13%-42%), and 8% (95% CI, 2%-22%), respectively. One-, 3-, and 5-y freedom from change in systemic therapy strategy was 76% (95% CI, 57%-87%), 65% (95% CI, 45%-79%), and 43% (95% CI, 19%-65%), respectively. Conclusion: In this proof-of-concept study, PSMA-guided MDT provided durable oncologic outcomes for oligometastatic RCC, even at 5 y. To our knowledge, this study had the first cohort uniformly undergoing PSMA-guided MDT and one of the longest follow-ups of MDT for oligometastatic RCC. With increasing availability, PSMA PET/CT can be rapidly instituted to select patients for MDT and improve outcomes for patients with oligometastatic RCC.
引用
- Udovicich C, Bressel M, Manji J, et al. PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study. J Nucl Med. 2025. PMID: 39978809. doi:10.2967/jnumed.124.268639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。